Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy

Cell Reports Medicine 2026 Open access

Read full text
Authors: Danhong Chen, Ran Xu, Xiaoyun Ye, Youmei Xiao, Mengfan Wang, Wanqiong Li, Feiyu Luo, Xiaoshuang Niu, Xia Yang, Ye Su, Wenxuan Zeng, Ying Liu
+8 more Wenzhi Shang, Yang Li, Xin Zhao, J Hu, Xiaoshuang Chen, Xueqin Zhu, Xinghua Sui, Yanfeng Gao
DOI: 10.1016/j.xcrm.2025.102568
Cited by: 4
References: 43

Abstract

T cell infiltration and activation in anti-PD-1-resistant tumor model. The BsPNEC platform integrates tumor-targeted delivery, magnetic resonance imaging (MRI) contrast capabilities, and robust inhibition of tumor growth. Our findings present a synergistic immunotherapeutic strategy that simultaneously skews immunosuppressive TME and amplifies T cell immune response.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Advanced Nanomaterials in Catalysis Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Cell Reports Medicine
Publisher
Elsevier BV
Volume
7
Issue
2
Pages
102568–102568
Publication date
21 January 2026
Language
EN